All Stories

  1. Domain-Adaptive Transfer Learning for HPV Lesion Classification in Whole Slide Images: A Patient-Level Pipeline Across the Cytology–Histology Continuum
  2. The Molecular Interplay Between p53-Mediated Ferroptosis and Non-Coding RNAs in Cancer
  3. Emerging role of endogenous peptides encoded by non-coding RNAs in cancer biology
  4. TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)
  5. TLR4 Downregulation Identifies High-Risk HPV Infection and Integration in H-SIL and Squamous Cell Carcinomas of the Uterine Cervix
  6. Why so much uncertainty about adjuvant HPV vaccines after local treatment? Can the discrepancy between the positive statistical results and the scientific community doubts be solved?
  7. Cross-reactive CD8+ T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs)
  8. Integrated plasma metabolomics and lipidomics profiling highlights distinctive signature of hepatocellular carcinoma in HCV patients
  9. Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations
  10. Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma
  11. Microorganisms-derived antigens for preventive anti-cancer vaccines
  12. Non-Classical HLA Class 1b and Hepatocellular Carcinoma
  13. Molecular mimicry and cancer vaccine development
  14. Immune profiling of SARS-CoV-2 epitopes in asymptomatic and symptomatic pediatric and adult patients
  15. The Molecular Interplay between Human Oncoviruses and Telomerase in Cancer Development
  16. Antigenic molecular mimicry in viral-mediated protection from cancer: the HIV case
  17. The Molecular Interplay between Human Oncoviruses and Telomerase in Cancer Development
  18. Antigenic molecular mimicry in viralmediated protection from cancer: the HIV case.
  19. Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data
  20. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)
  21. Molecular mimicry between tumor associated antigens and microbiota-derived epitopes
  22. Hepatocellular Carcinoma Intrinsic Cell Death Regulates Immune Response and Prognosis
  23. Molecular Mimicry Between Tumor Associated Antigens and Microbiota-derived Epitopes
  24. Profiling the HCV Immune Response in Patients with Chronic Liver Diseases and Hepatocellular Carcinoma by Peptide Microarray Analysis
  25. Mutations in the telomerase reverse transcriptase promoter and PIK3CA gene are common events in penile squamous cell carcinoma of Italian and Ugandan patients
  26. Bimodal Antibody-Titer Decline Following BNT162b2 Mrna Anti-SARS-Cov-2 Vaccination In Healthcare Workers of The INT – IRCCS “Fondazione Pascale” Cancer Center (Naples, Italy)
  27. Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
  28. Novel Molecular Targets for Hepatocellular Carcinoma
  29. Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides
  30. MHC-Optimized Peptide Scaffold for Improved Antigen Presentation and Anti-Tumor Response
  31. Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma
  32. HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine
  33. Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).
  34. The Role of circRNAs in Human Papillomavirus (HPV)-Associated Cancers
  35. PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus‐related diseases
  36. Human Papillomavirus and Cancers
  37. The clinical and translational research activities at the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy) during the COVID-19 pandemic
  38. Detection of Human Papillomaviruses in the Nasopharynx of Breastfed Infants: New Findings and Meta-Analysis
  39. Modeling the epithelial-mesenchymal transition process in a 3D organotypic cervical neoplasia
  40. Detection of a large spectrum of viral infections in conjunctival premalignant and malignant lesions
  41. Covid‐19: Time for a paradigm change
  42. Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities
  43. Transoral robotic surgery in head and neck district: a retrospective study on 67 patients treated in a single center
  44. The Role of RNA Splicing Factors in Cancer: Regulation of Viral and Human Gene Expression in Human Papillomavirus-Related Cervical Cancer
  45. SARS-CoV-2 RNA polymerase as target for antiviral therapy
  46. Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines
  47. The Role of microRNAs, Long Non-coding RNAs, and Circular RNAs in Cervical Cancer
  48. Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy
  49. High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy
  50. Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms
  51. Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
  52. Updates on the Role of Molecular Alterations and NOTCH Signaling in the Development of Neuroendocrine Neoplasms
  53. Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma
  54. Corrigendum to “New vaccination strategies in liver cancer” [Cytokine Growth Factor Rev. 36 (2017) 125–129]
  55. Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma
  56. Uncovering “hidden” mutations in hepatocellular carcinoma: the use of droplet digital PCR to detect TERT promoter mutations
  57. Cancer Diagnostic and Predictive Biomarkers 2018
  58. Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients
  59. The Role of Sensing Peptides in the Cross-talk between Microbiota and Human Cancer Cells
  60. Prevalence of “unclassified” HPV genotypes among women with abnormal cytology
  61. Cancer Vaccine for HCC
  62. Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers
  63. HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.
  64. Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma
  65. Large deletion at the CDC73 gene locus and search for predictive markers of the presence of a CDC73 genetic lesion
  66. P-G5 Differential immune response to HCV peptides as cancer-progression biomarkers of HCV-infections
  67. The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma
  68. Cellular prognostic markers in hepatitis-related hepatocellular carcinoma
  69. Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia
  70. Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents
  71. Sex Hormone Receptors in Benign and Malignant Salivary Gland Tumors: Prognostic and Predictive Role
  72. Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting
  73. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
  74. New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology
  75. New vaccination strategies in liver cancer
  76. New cell block containing agarose for cytopathological diagnosis of tumor samples
  77. Accuracy of Fine Needle Cytology in Histological Prediction of Papillary Thyroid Carcinoma Variants: a Prospective Study
  78. Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma
  79. Use of adjuvants for immunotherapy
  80. Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma
  81. An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
  82. Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference
  83. An Engineered Cell-Instructive Stroma for the Fabrication of a Novel Full Thickness Human Cervix Equivalent In Vitro
  84. Comparative analysis of HPV16 gene expression profiles in cervical and in oropharyngeal squamous cell carcinoma
  85. TERT promoter and CTNNB1 gene mutations represent cancer signatures specific for hepatitis B and hepatitis C related hepatocellular carcinoma
  86. MDM2 gene polymorphisms and risk of classic Kaposi’s sarcoma among Iranian patients
  87. Cancer Diagnostic and Predictive Biomarkers 2016
  88. Virus-Like Particles
  89. Vaccine Approaches in Hepatocellular Carcinoma
  90. Discovery to first-in-man studies of a multi-peptide-based hepatocellular carcinoma vaccine adjuvanted with CV8102 (RNAdjuvant) – HEPAVAC
  91. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial
  92. Immunological effects of a novel RNA-based adjuvant in liver cancer patients
  93. Abstract A046: Identification and validation of HCC-specific gene transcriptional signature for tumor antigen discovery
  94. Abstract A044: Immunological effects of a novel RNA-based adjuvant in liver cancer patients
  95. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma
  96. Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery
  97. Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types
  98. Detection of human papillomavirus DNA in peri-tumor tissues and pelvic lymph nodes as potential molecular marker of micrometastasis in cervical cancer
  99. Combinatorial immunotherapy strategies for hepatocellular carcinoma
  100. Cancer vaccines for hepatocellular carcinoma: future directions
  101. Candidate Soluble Immune Mediators in Young Women with High-Risk Human Papillomavirus Infection: High Expression of Chemokines Promoting Angiogenesis and Cell Proliferation
  102. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections
  103. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR
  104. A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice
  105. Infectious Agents and Cancer reviewer acknowledgement 2015
  106. A-108 Viral and cellular biomarkers in HPV-related cancers
  107. Functional characterization of biodegradable nanoparticles as antigen delivery system
  108. Systems Biology Approach for Cancer Vaccine Development and Evaluation
  109. Developments in cancer vaccines for hepatocellular carcinoma
  110. An overview of new biomolecular pathways in pathogen-related cancers
  111. Cancer biomarkers
  112. Cellular prognostic markers in hepatocellular carcinoma
  113. Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer
  114. Brooke-Spiegler syndrome presenting multiple concurrent cutaneous and parotid gland neoplasms: Cytologic findings on fine-needle sample and description of a novel mutation of the CYLD gene
  115. Correction: Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases
  116. Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model
  117. Tobacco Smoke Activates Human Papillomavirus 16 p97 Promoter and Cooperates with High-Risk E6/E7 for Oxidative DNA Damage in Lung Cells
  118. Combined Papillary and Mucoepidermoid Carcinoma of the Thyroid Gland: a Possible Collision Tumor Diagnosed on Fine-Needle Cytology. Report of a Case with Immunocytochemical and Molecular Correlations
  119. Primary Peritoneal Clear Cell Carcinoma Versus Ovarian Carcinoma Versus Malignant Transformation of Endometriosis
  120. Detection of high mobility group A2 specific mRNA in the plasma of patients affected by epithelial ovarian cancer
  121. Genetic Diversity of the KIR/HLA System and Susceptibility to Hepatitis C Virus-Related Diseases
  122. Follicular thyroid carcinoma with skull metastases
  123. Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies
  124. Cancer Diagnostic and Predictive Biomarkers 2015
  125. Identification of Human Herpesvirus 8 Sequences in Conjunctiva Intraepithelial Neoplasia and Squamous Cell Carcinoma of Ugandan Patients
  126. The XIX century smallpox prevention in Naples and the risk of transmission of human blood-related pathogens
  127. Virus-like Particles
  128. HCV-related liver and lymphoproliferative diseases: association with polymorphisms of IL28B and TLR2
  129. CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not
  130. Antigen-specific vaccines for cancer treatment
  131. Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study
  132. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix
  133. HPV-related oropharyngeal cancers: From pathogenesis to new therapeutic approaches
  134. Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines
  135. Systems vaccinology for cancer vaccine development
  136. 150 Carcinogenesis of HPV
  137. Human Papillomavirus Infection and Cervical Neoplasia among Migrant Women Living in Italy
  138. Emotional false memories in children with learning disabilities
  139. CDK/CCN and CDKI Alterations for Cancer Prognosis and Therapeutic Predictivity
  140. The Functional Role of MnSOD as a Biomarker of Human Diseases and Therapeutic Potential of a New Isoform of a Human Recombinant MnSOD
  141. Developments in virus-like particle-based vaccines for HIV
  142. Duodenal gangliocytic paraganglioma, a rare entity among GEP-NET: a case report with immunohistochemical and molecular study
  143. Cancer Diagnostic and Predictive Biomarkers
  144. Electrochemotherapy as “new standard of care” treatment for cutaneous Kaposi's sarcoma
  145. Corrigendum to: “Challenges in cancer vaccine development for hepatocellular carcinoma” [J Hepatol 2013;59:897–903]
  146. Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach
  147. Virus-like particle vaccines for the prevention of human papillomavirus infection
  148. Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection
  149. Cancer-Associated CD43 Glycoforms as Target of Immunotherapy
  150. Challenges in cancer vaccine development for hepatocellular carcinoma
  151. VLPs and particle strategies for cancer vaccines
  152. New developments in cancer vaccines
  153. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections
  154. Kaposi’s sarcoma: Etiology and pathogenesis, inducing factors, causal associations, and treatments: Facts and controversies
  155. High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer
  156. Infections and cancer: debate about using vaccines as a cancer control tool
  157. Development of a stable insect cell line constitutively expressing rotavirus VP2
  158. Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: A systematic review
  159. Molecular Signatures Associated with HCV-Induced Hepatocellular Carcinoma and Liver Metastasis
  160. Developments in virus-like particle-based vaccines for HIV
  161. The application of virus-like particles to human diseases
  162. Lung cancer diagnosis on ovary mass: a case report
  163. Massive edema of ovary with cytogenetic alteration of chromosome 12q13-15 in adolescent patient: a case report
  164. Expression Analysis of SPARC/Osteonectin in Oral Squamous Cell Carcinoma Patients: From Saliva to Surgical Specimen
  165. Viral and Cellular Biomarkers in the Diagnosis of Cervical Intraepithelial Neoplasia and Cancer
  166. Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate
  167. Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer
  168. Identification and sequence analysis of a novel human leukocyte antigen alleleB*51:141
  169. Oncolytic virus therapies
  170. Multiparametric Analyses of Human PBMCs Loaded Ex Vivo with a Candidate Idiotype Vaccine for HCV-Related Lymphoproliferative Disorders
  171. HIV p24 as Scaffold for Presenting Conformational HIV Env Antigens
  172. Immunogenomics approaches for vaccine evaluation
  173. Functional Interaction between Human Papillomavirus Type 16 E6 and E7 Oncoproteins and Cigarette Smoke Components in Lung Epithelial Cells
  174. Advances in viral oncology research: summary of the 3rd International Meeting
  175. Immunogenicity of HIV Virus-Like Particles in Rhesus Macaques by Intranasal Administration
  176. Characterization of the Human Papillomavirus (HPV) Integration Sites into Genital Cancers
  177. Quality of life, lifestyle behavior and employment experience: A comparison between young and midlife survivors of gynecology early stage cancers
  178. Axillary node metastasis from differentiated thyroid carcinoma with hürthle and signet ring cell differentiation. A case of disseminated thyroid cancer with peculiar histologic findings
  179. Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients
  180. Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization
  181. Effects of adjuvants on IgG subclasses elicited by virus-like Particles
  182. HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies
  183. Innate immunity and hepatitis C virus infection: a microarray’s view
  184. Assessment ofChlamydia trachomatisinfection among Eastern European and West African women immigrants in South Italy
  185. Developments in virus-like particle-based vaccines for infectious diseases and cancer
  186. Plant-derived anti-HIV-1 proteins
  187. Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?
  188. Can HIV p24 Be a Suitable Scaffold for Presenting Env Antigens?
  189. PlantPIs – An Interactive Web Resource on Plant Protease Inhibitors
  190. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins
  191. HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line
  192. High prevalence of human papillomavirus infection in Eastern European and West African women immigrants in South Italy
  193. New adjuvants in evolving vaccine strategies
  194. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix
  195. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma in Italian patients
  196. Systems biology applied to vaccine and immunotherapy development
  197. Metastatic breast carcinoma to parathyroid adenoma on fine needle cytology sample: Report of a case
  198. Translating Tumor Antigens into Cancer Vaccines
  199. MDM2 and CDKN1A gene polymorphisms and risk of Kaposi’s sarcoma in African and Caucasian patients
  200. Immune Signatures and Systems Biology of Vaccines
  201. Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system
  202. Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy
  203. Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches
  204. Human papillomavirus infection in urine samples from male renal transplant patients
  205. Virus-Like Particles as Particulate Vaccines
  206. Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era
  207. Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders
  208. FEZ1/LZTS1 protein expression in ovarian cancer
  209. Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies
  210. Virus-like particle vaccines and adjuvants: the HPV paradigm
  211. Adhesion molecules and p16 expression in endocervical adenocarcinoma
  212. Molecular immune signatures of HIV-1 vaccines in human PBMCs
  213. Short Communication: Limited Induction of IL-10 in PBMCs from HIV-Infected Subjects Treated with HIV-VLPs
  214. 183 Morphogenomic immune responsiveness to preventive/therapeutic vaccines
  215. 210 Peripheral blood mononuclear cells activated by HIV-VLPs in correlation with HIV-1 seropositivity status
  216. Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy
  217. Fine-needle cytology of metastatic endometrioid neoplasms: Experience with eight cases
  218. Detection of mucosal and cutaneous human papillomaviruses in oesophagitis, squamous cell carcinoma and adenocarcinoma of the oesophagus
  219. Unsung Hero Robert C. Gallo
  220. Spontaneous infarction of pleomorphic adenoma: Report of a case simulating malignancy on fine-needle cytology sample
  221. Sclerosing polycystic adenosis of the parotid gland: Report of one case diagnosed by fine-needle cytology with in situ malignant transformation
  222. Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma
  223. P12-03. Generation of novel recombinant HIV-1 glycoproteins for expression on virus like particles
  224. P19-11. Generation of virus-like particles expressing different HIV-1 glycoproteins for induction of broadly neutralizing antibodies
  225. TP53 Codon 72 Polymorphism in Classic, Endemic and Epidemic Kaposi’s Sarcoma in African and Caucasian Patients
  226. A pilot study on the distribution of human papillomavirus genotypes and HPV-16 variants in cervical neoplastic lesions from Ecuadorian women
  227. Th2 Polarization in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus (HIV)-Infected Subjects, as Activated by HIV Virus-Like Particles
  228. Analysis of TP53 codon 72 polymorphism in HPV-positive and HPV-negative penile carcinoma
  229. Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women
  230. Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco
  231. Clear-cell myoepithelial carcinoma of the salivary glands: A clinicopathologic, immunohistochemical, and ultrastructural study of two cases involving the submandibular gland with review of the literature
  232. Correction
  233. Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation
  234. Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy
  235. HIV Type 1 Subtype A Epidemic in Injecting Drug User (IDU) Communities in Iran
  236. DNA–VLP prime–boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity
  237. Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications
  238. Human papillomavirus genotypes and HPV16 variants in penile carcinoma
  239. Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example
  240. Structured particles for antigen presentation
  241. Genetic and Phylogenetic Characterization of Structural Genes from Non-B HIV-1 Subtypes in Italy
  242. Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses
  243. Evaluating the role of human papillomaviruses in conjunctival neoplasia
  244. Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population
  245. Baculovirus-Derived HIV-1 Virus-Like Particles (VLP) Activate Dendritic Cells and Are Cross-Presented to Induce In Vitro T-Cell Response
  246. Induction of Systemic and Mucosal Cross-Clade Neutralizing Antibodies in BALB/c Mice Immunized with Human Immunodeficiency Virus Type 1 Clade A Virus-Like Particles Administered by Different Routes of Inoculation
  247. Evaluation of a modified version of Heteroduplex Mobility Assay for rapid screening of HIV-1 isolates in epidemics characterized by mono/dual clade predominance
  248. TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda
  249. Screening of HIV-1 Isolates by Reverse Heteroduplex Mobility Assay and Identification of Non-B Subtypes in Italy
  250. Human papillomaviruses and cervical lesions in the Italian population
  251. Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer
  252. Kaposi's sarcoma: aetiopathogenesis, histology and clinical features
  253. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A
  254. High efficient production of Pr55gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A
  255. Identification and functional analysis of sequence rearrangements in the long control region of human papillomavirus type 16 Af-1 variants isolated from Ugandan penile carcinomas
  256. The Uganda study on HPV variants and genital cancers
  257. Warthin-like tumour of the thyroid gland: RET/PTC expression indicates it is a variant of papillary carcinoma
  258. Sequence Note: A Novel Glycoprotein 120 Sequence from an HIV Type 1 Isolate of the A Clade Identified in North Uganda
  259. Sequence variations and viral genomic state of human papillomavirus type 16 in penile carcinomas from Ugandan patients.
  260. Post-operative complications after completion thyroidectomy for differentiated thyroid cancer
  261. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies
  262. Analysis of HIV-1 env gene V3 loop sequence in a southern Italian cohort of intravenous drug users
  263. Human Immunodeficiency Virus Type 1 tat Gene Enhances Human Papillomavirus Early Gene Expression
  264. Human papillomavirus (hpv) DNA in penile carcinomas and in two cell lines from high-incidence areas for genital cancers in Africa
  265. Role of HIV as Cofactor in HPV Oncogenesis: In vitro Evidences of Virus Interactions
  266. Role of HIV-1 Tat in the Pathogenesis of AIDS-Associated Kaposi�s Sarcoma1
  267. V3 Region Genotyping of HIV Isolates in Northern Uganda: Heteroduplex Mobility Assay, Nucleotide Sequence and Phylogenese Analysis